最新研报
共 12,855 份研报 · 国内 8,065 · 国外 4,059 · 全库按发布时间排序
辉瑞(PFE.US):三季度业绩前瞻——预计艾乐妥(Eliquis)将再度带动业绩指引上调
Pfizer Inc. (PFE): 3Q Earnings Preview – Anticipating Another Eliquis Driven Guidance Raise
摩根大通·2026-10-09·12 页·美股
即将开展的RAINFOL-02试验无进展生存期(PFS)大概率取得阳性结果,但支撑总生存期(OS)及保持竞争力所需的获益幅度门槛较高
Genmab A/S (GMAB.CO): Upcoming RAINFOL-02 trial likely to be successful on PFS, though magnitude of the benefit needed to support OS and to be competitive is a high bar
摩根大通·2026-10-09·13 页·其它
丰田汽车(7203.T):中国合资企业重组;后续重点关注销售渠道与平台整合带来的协同效应
Toyota Motor (7203): Reorganization of Chinese joint ventures; sales network and platform integration synergies in focus moving forward
摩根大通·2026-10-09·10 页·其它
飞利浦(PHG.AS)2026年三季度一致预期对比:调整后EBITA较市场一致预期低3.6%,但本季度业务疲软早已被充分提示
Philips (PHG.AS): Q3'26 consensus comparison. 3.6% below on adj EBITA, although the soft quarter is well flagged
摩根大通·2026-10-09·13 页·其它
摩根大通-电气设备与多元工业:板块回调带来一定的中期补涨空间;将DD、ITW下调至中性评级;将TT上调至超配,CARR维持中性评级
Electrical Equipment & Multi-Industry: Pullback creates some modest mid-cycle catch-up potential; Downgrade DD, ITW to N; Moving to ratings on TT at OW, CARR at N
摩根大通·2026-10-09·91 页·电气设备
代理业务基准对比:PUB登顶三季度排行榜,为连续8年跑赢市场奠定基础
PUB tops Q3 league table, laying foundation for 8th year of outperformance
摩根大通·2026-10-09·42 页·文化传媒
大型银行:利率上行对总权益资本(TCE)产生一定冲击;部分银行持有至到期投资(HTM)承压更大但风险可控
Large Cap Banks: Some Hit To TCE From Higher Rates - Bigger Hit From HTM For Some Banks But Manageable
摩根大通·2026-10-09·9 页·金融
财产及意外险直保与再保险机构2026年三季度前瞻:商业险板块估值已充分定价,再保险公司估值相对合理
P&C Re/Insurers 3Q26 Preview: Commercial Lines Seem Fully Valued, Reinsurers Look More Reasonable
摩根大通·2026-10-09·130 页·金融
法国银行业:历史再度上演
French Banks: Et Rebelote!
摩根大通·2026-10-09·12 页·金融
IT服务与电信:盈利展望(7-9月)——冷门个股有望反弹
IT Services & Telecoms: Earnings Outlook (Jul-Sep): Hopes for a comeback by unpopular stocks
摩根大通·2026-10-09·13 页·信息技术
摩根大通-CSL(CSL.AX):将于2027年底恢复使用哈美尼斯特(Haemonetics)设备采集血浆;若市场环境发生变化,此举是公司一系列重大战略决策的一部分;维持增持评级
Switching plasma collection back to Haemonetics by end-2027; Part of a broader pattern of bold decision-making if conditions have changed; Overweight
摩根大通·2026-10-09·8 页·其它
C4 Therapeutics(CCCC.US):首次覆盖给予“增持”评级,看好Cemsidomide在多发性骨髓瘤中的潜力
C4 Therapeutics: Initiating at Overweight on Cemsidomide's Potential in Multiple Myeloma
摩根大通·2026-10-09·28 页·美股
中国汽车制造商——CBG资金流向更新(汽车-比亚迪、电池-宁德时代、玻璃-福耀):福耀具备不错的风险收益比及三季度业绩前瞻
China Auto Manufacturers — CBG Fund Flow Update (Car-BYD, Battery-CATL, Glass-Fuyao)—Fuyao's Attractive Risk-Reward & 3Q Preview
花旗·2026-10-09·13 页·交运设备
速腾聚创(2498.HK):凭借高级驾驶辅助系统激光雷达的强劲交付,三季度出货量较预期高出5%
RoboSense (2498.HK) 3Q Shipment Beat by 5% with Strong ADAS LiDAR Delivery
花旗·2026-10-09·12 页·港股
诺和诺德(NOVOb.CO):2026年三季度前瞻与模型更新;下调目标价至296丹麦克朗
Novo Nordisk A/S (NOVOb.CO) 3Q26 Preview & Model Update; Lowering TP to DKK296
花旗·2026-10-09·17 页·其它
法罗威集团(FER.MC)2026年前9个月业绩前瞻:定价能力仍是核心驱动因素
Ferrovial NV (FER.MC): 9M26e preview: Pricing power remains the key driver
花旗·2026-10-09·11 页·其它
东证指数(TOPIX)新一代复盘:成分大范围调整,资金流向影响显著
TOPIX Next-Generation Review: Broad Reshuffle, Significant Flow Implications
北京高华证券·2026-10-09·8 页·市场策略
迅销集团(9983.T)业绩复盘:2027财年8月业绩指引超预期;LifeWear理念渗透率持续提升,管理层对东南亚市场信心增强;维持"买入"
Fast Retailing (9983.T) Earnings Review: FY8/27 guidance above expectations; LifeWear penetration continues, mgmt more confident in Southeast Asia than before; maintain Buy
高盛·2026-10-09·8 页·其它
汇川技术(300124.SZ):三季度业绩前瞻:大概率平稳收官;因工业自动化订单增长轨迹放缓下调目标价与盈利预测
汇川技术 (300124.SZ): 3Q preview: likely a stable quarter; Lower TP/EPS on moderating IA order growth trajectory ahead
北京高华证券·2026-10-09·12 页·创业板
策略快讯:具备美国业务敞口的标的(GSSTAMER)对欧元兑美元汇率最为敏感
Strategy Espresso: US exposed (GSSTAMER) are most sensitive to EUR/USD
北京高华证券·2026-10-09·8 页·市场策略
显示 5141 - 5160 条,共 12,855 条